Zogenix – About the Company

Zogenix (NasdaqGM: ZGNX) is biotechnology company developing two late-stage assets to address unmet medical needs in the treatment of central nervous system (CNS) disorders. The Company’s lead program, ZX008, is a small molecule that has been shown to greatly reduce seizure frequency in patients with Dravet syndrome. The Company plans to initiate pivotal Phase III trials in the fourth quarter of 2015. Zogenix is also developing a long-acting atypical antipsychotic Relday, a subcutaneous form of Johnson & Johnson’s Risperdal Consta (risperidone), for schizophrenia patients. The Company is currently conducting a Phase Ib trial for Relday and expects to move into a pivotal Phase III trial in the second half of 2016.